These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 33806139)

  • 1. Design and Synthesis of Novel Symmetric Fluorene-2,7-Diamine Derivatives as Potent Hepatitis C Virus Inhibitors.
    Mousa MHA; Ahmed NS; Schwedtmann K; Frakolaki E; Vassilaki N; Zoidis G; Weigand JJ; Abadi AH
    Pharmaceuticals (Basel); 2021 Mar; 14(4):. PubMed ID: 33806139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel benzidine and diaminofluorene prolinamide derivatives as potent hepatitis C virus NS5A inhibitors.
    Bae IH; Kim HS; You Y; Chough C; Choe W; Seon MK; Lee SG; Keum G; Jang SK; Moon Kim B
    Eur J Med Chem; 2015 Aug; 101():163-78. PubMed ID: 26134551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symmetric benzidine derivatives as anti-HCV agents: Insight into the nature, stereochemistry of the capping amino acid and the size of the terminal capping carbamates.
    Abdel Karim SE; Youssef YH; Abdel-Halim M; Frakolaki E; Vassilaki N; Zoidis G; Ahmed NS; Abadi AH
    Bioorg Chem; 2020 Sep; 102():104089. PubMed ID: 32717691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symmetric Anti-HCV Agents: Synthesis, Antiviral Properties, and Conformational Aspects of Core Scaffolds.
    Leila ARS; Mousa MHA; Frakolaki E; Vassilaki N; Bartenschlager R; Zoidis G; Abdel-Halim M; Abadi AH
    ACS Omega; 2019 Jul; 4(7):11440-11454. PubMed ID: 31460249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
    McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
    Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
    J Virol; 2019 May; 93(10):. PubMed ID: 30842319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Synthesis of Novel Bis-Imidazolyl Phenyl Butadiyne Derivatives as HCV NS5A Inhibitors.
    Hamdy J; Emadeldin N; Hamed MM; Frakolaki E; Katsamakas S; Vassilaki N; Zoidis G; Hirsch AKH; Abdel-Halim M; Abadi AH
    Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent Hepatitis C Virus NS5A Inhibitors Containing a Benzidine Core.
    Bae IH; Choi JK; Chough C; Keum SJ; Kim H; Jang SK; Kim BM
    ACS Med Chem Lett; 2014 Mar; 5(3):255-8. PubMed ID: 24900814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
    Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
    Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Discovery of Conformationally Constrained Bicyclic Peptidomimetics as Potent Hepatitis C NS5A Inhibitors.
    Kazmierski WM; Miriyala N; Johnson DK; Baskaran S
    ACS Med Chem Lett; 2021 Nov; 12(11):1649-1655. PubMed ID: 34790290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Second-generation of Highly Potent Hepatitis C Virus (HCV) NS3/4A Protease Inhibitors: Evolutionary Design Based on Tailor-made Amino Acids, Synthesis and Major Features of Bio-activity.
    Wang S; Wang Y; Wang J; Sato T; Izawa K; Soloshonok VA; Liu H
    Curr Pharm Des; 2017; 23(30):4493-4554. PubMed ID: 28530544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system.
    Pomeroy JJ; Drusano GL; Rodriquez JL; Brown AN
    Antiviral Res; 2017 Oct; 146():149-152. PubMed ID: 28882564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfur(vi) fluoride exchange as a key reaction for synthesizing biaryl sulfate core derivatives as potent hepatitis C virus NS5A inhibitors and their structure-activity relationship studies.
    You Y; Kim HS; Park JW; Keum G; Jang SK; Kim BM
    RSC Adv; 2018 Sep; 8(55):31803-31821. PubMed ID: 35548241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes.
    Romine JL; St Laurent DR; Leet JE; Martin SW; Serrano-Wu MH; Yang F; Gao M; O'Boyle DR; Lemm JA; Sun JH; Nower PT; Huang XS; Deshpande MS; Meanwell NA; Snyder LB
    ACS Med Chem Lett; 2011 Mar; 2(3):224-9. PubMed ID: 24900306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
    De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
    J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry.
    Ahmed M; Pal A; Houghton M; Barakat K
    ACS Infect Dis; 2016 Nov; 2(11):872-881. PubMed ID: 27933783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
    Frey A; Piras-Straub K; Walker A; Timm J; Gerken G; Herzer K
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29111569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors.
    Giroux S; Xu J; Reddy TJ; Morris M; Cottrell KM; Cadilhac C; Henderson JA; Nicolas O; Bilimoria D; Denis F; Mani N; Ewing N; Shawgo R; L'Heureux L; Selliah S; Chan L; Chauret N; Berlioz-Seux F; Namchuk MN; Grillot AL; Bennani YL; Das SK; Maxwell JP
    ACS Med Chem Lett; 2014 Mar; 5(3):240-3. PubMed ID: 24900811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?
    Janardhan SV; Reau NS
    Hepat Med; 2015; 7():11-20. PubMed ID: 25926761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
    El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
    Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.